Flyte Aviation, Inc.

For the period ended Jul 25, 2025. Filed Jun 9, 2025.

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jul 25, 2025 · Filed Jun 9, 2025

VTAK$0.15-0.7%Stored close · as of Oct 2, 2026

See the whole filing, with its images and exhibits

Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

(Amendment No. _____)

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))
☒	Definitive Proxy Statement
☐	Definitive Additional Materials
☐	Soliciting Material Pursuant to §240.14a‑12

Catheter Precision, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒	No fee required.
☐	Fee paid previously with preliminary materials.
☐	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

1670 Highway 160 West Suite 205

Fort Mill, SC 29708

(973) 691-2000

To our Stockholders:

We are pleased to invite you to attend the annual meeting of stockholders (the “Annual Meeting”) of Catheter Precision, Inc., to be held on July 25, 2025 at 11:00 a.m. Eastern time, or at any adjournment or postponement thereof. The Annual Meeting will be a virtual meeting of stockholders. You are invited to attend and vote your shares at the Annual Meeting live via internet webcast so long as you register to attend the Annual Meeting atweb.viewproxy.com/VTAK/2025by 5:00 p.m. Eastern time on July 24, 2025 (the “Registration Deadline”). Questions will need to be submitted prior to the Annual Meeting. To submit questions, please visitweb.viewproxy.com/VTAK/2025.You will not be able to attend the Annual Meeting in person. At this year’s Annual Meeting, our stockholders will be asked to:

●	elect one Class I director (“Proposal No. 1”);

●

approve, in accordance with NYSE American Company Guide Section 713(a), the issuance of up to 4,285,716 shares of our common stock, par value $0.0001 per share (“Common Stock”), upon the exercise of our Series L Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately following the date upon which our stockholders approve this proposal (the “Series L Warrant Exercise Proposal” or “Proposal No. 2”);

●

approve, in accordance with NYSE American Company Guide Section 713(a), the issuance of up to 8,574,000 shares of our Common Stock upon conversion of our Series B Convertible Preferred Stock, par value $0.0001 per share, with the right for such potential conversion to occur immediately following the date upon which our stockholders approve this proposal (the “Preferred Conversion Proposal” or “Proposal No. 3”);

●

approve, in accordance with NYSE American Company Guide Section 713(a), the issuance of up to 257,143 shares of our Common Stock upon the exercise of our 2025 Placement Agent Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately following the date upon which our stockholders approve this proposal (the “2025 Placement Agent Warrant Exercise Proposal” or “Proposal No. 4”);

●

approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our Common Stock that is issued and outstanding or held in treasury at a stock split ratio of between 1-for-5 and 1-for-19, inclusive, which ratio will be selected at the sole discretion of our Board of Directors or a duly authorized committee thereof at any whole number in the above range (the “Reverse Stock Split”), with cash paid for any fractional shares that would otherwise be issued as a result of the Reverse Stock Split; provided, that the Board may abandon the Reverse Stock Split in its sole discretion (the “Reverse Stock Split Proposal” or “Proposal No. 5”)

●	ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2025 (the “Auditor Ratification Proposal” or “Proposal No. 6”); and

●	transact such other business that may properly come before the Annual Meeting.

Details regarding how to attend the Annual Meeting and the business to be conducted at the Annual Meeting are more fully described in the accompanying notice of Annual Meeting of stockholders and proxy statement.

Your vote is important. Regardless of whether you plan to attend the Annual Meeting, it is important that your shares be represented and voted at the Annual Meeting, and we hope you will vote as soon as possible. You may vote by proxy via the Internet, by telephone, or by mail, according to the instructions on the enclosed proxy card or voting instruction card. Voting over the Internet or by telephone, by written proxy or voting instruction card will ensure your representation at the Annual Meeting regardless of whether you attend the Annual Meeting.

Thank you for your ongoing support of, and continued interest in, Catheter Precision, Inc.

Sincerely,

David A. Jenkins

Executive Chairman of the Board

Fort Mill, SC

June 9, 2025

The date of this proxy statement is June 9, 2025, and it is being mailed to stockholders on or about that same date.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on July 25, 2025. Our Proxy Statement and Annual Report to Stockholders, and the Notice of the Meeting, are available atweb.viewproxy.com/VTAK/2025.

1670 Highway 160 West Suite 205 Fort Mill, SC 29708 USA Main: 973-691-2000 Fax: 973-691-7573

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

Time and Date	11:00 a.m. Eastern time, on Friday, July 25, 2025, or any adjournment or postponement thereof.
Webcast Address	web.viewproxy.com/VTAK/2025
Items of Business	(1)	To elect one Class I director (“Proposal No. 1”);
	(2)	To approve, in accordance with NYSE American Company Guide Section 713(a), the issuance of up to 4,285,716 shares of our Common Stock upon the exercise of our Series L Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately following the date upon which our stockholders approve this proposal (the “Series L Warrant Exercise Proposal” or “Proposal No. 2”);
	(3)	To approve, in accordance with NYSE American Company Guide Section 713(a), the issuance of up to 8,574,000 shares of our Common Stock upon conversion of our Series B Convertible Preferred Stock, par value $0.0001 per share, with the right for such potential conversion to occur immediately following the date upon which our stockholders approve this proposal (the “Preferred Conversion Proposal” or “Proposal No. 3”);
	(4)	To approve, in accordance with NYSE American Company Guide Section 713(a), the issuance of up to 257,143 shares of our Common Stock upon the exercise of our 2025 Placement Agent Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately following the date upon which our stockholders approve this proposal (the “2025 Placement Agent Warrant Exercise Proposal” or “Proposal No. 4”);
	(5)	To approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our Common Stock that is issued and outstanding or held in treasury at a stock split ratio of between 1-for 5 and 1-for-19, inclusive, which ratio will be selected at the sole discretion of our Board of Directors or a duly authorized committee thereof at any whole number in the above range (the “Reverse Stock Split”), with cash paid for any fractional shares that would otherwise be issued as a result of the Reverse Stock Split; provided, that the Board may abandon the Reverse Stock Split in its sole discretion (the “Reverse Stock Split Proposal” or “Proposal No. 5”)
	(6)	To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2025 (the “Auditor Ratification Proposal” or “Proposal No. 6”); and

	Any action on the items of business described above may be considered at the Annual Meeting at the time and on the date specified above or at any time and date to which the Annual Meeting may be properly adjourned or postponed.
	(7)	To transact such other business that may properly come before the Annual Meeting.
Record Date	June 5, 2025. Only stockholders of record of our Common Stock as of the close of business on Thursday, June 5, 2025, are entitled to notice of and to vote at the Annual Meeting.

Meeting Admission

You are invited to attend the Annual Meeting live via webcast if you are a stockholder of record or a beneficial owner of shares of our Common Stock, in each case, as of June 5, 2025. Prior registration to attend the Annual Meeting at web.viewproxy.com/VTAK/2025 is required by 5:00 p.m. Eastern time on July 24, 2025. Instructions regarding how to connect and participate live via the Internet, including how to demonstrate proof of stock ownership, are posted at web.viewproxy.com/VTAK/2025.

Voting

Your vote is very important. You may vote by proxy via the Internet, by telephone, or by mail, according to the instructions on the enclosed proxy card or voting instruction card. For specific instructions on how to vote your shares, please refer to the section entitled Questions and Answers beginning on page 1 of the accompanying proxy statement.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be Held on Friday, July 25, 2025. The 2025 Proxy Statement and 2024 Annual Report to security holders are available atweb.viewproxy.com/VTAK/2025 and are available from the SEC on its website atwww.sec.gov.

By order of the Board of Directors

David A. Jenkins

Executive Chairman of the Board

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.